(Q44072762)

29 November 2017

Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan (English)

1 reference

29 November 2017

0 references

1 reference

Chin-Hsiao Tseng

1

1 reference

PubMed ID

23877016

29 November 2017

language of work or name

English

0 references

publication date

20 July 2013

1 reference

29 November 2017

1 reference

29 November 2017

131

1 reference

29 November 2017

1

1 reference

29 November 2017

135-139

1 reference

Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms.

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Diabetes and risk of prostate cancer: a study using the National Health Insurance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Use of metformin and the risk of ovarian cancer: a case-control analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Relationships of uterine and ovarian tumors to pre-existing chronic conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Diabetes mellitus and ovarian cancer (Sweden).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

The impact of diabetes on survival in women with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

The role of dysregulated glucose metabolism in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Glucose as a prognostic factor in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Taiwan's new national health insurance program: genesis and experience so far.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2013.07.087

10.1016/J.YGYNO.2013.07.087

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

23877016